Lactoferrin Modified Release Formulation for AIEC Invasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) associated with Adherent-invasive Escherichia coli (AIEC) invasion often result in significant side-effects due to prolonged use of antibiotics, anti-inflammatory drugs, and corticosteroids, necessitating a more effective and side-effect-free therapeutic option.
Innovation Solution
A modified release formulation comprising bovine lactoferrin, which inhibits AIEC invasion of intestinal epithelial cells without reducing inflammation, is developed, utilizing a controlled release system that ensures localized or systemic activity with immediate topical or systemic availability, preventing AIEC adhesion and internalization in a dose-dependent manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics, anti-inflammatory drugs and corticosteroids are used to treat IBD associated with AIEC invasion, then the infection and inflammation are reduced, but significant side-effects occur due to prolonged use
Solution Approach 1:
Lactoferrin acts as an intermediary substance that mediates the treatment of AIEC invasion. It binds to AIEC bacteria and inhibits their ability to adhere to and invade intestinal epithelial cells, while also modulating the immune response. This intermediary approach provides therapeutic effect without the direct toxicity of antibiotics or the significant side-effects of prolonged corticosteroid use
Solution Approach 2:
The invention changes the therapeutic parameter from conventional antibiotics and corticosteroids to lactoferrin, a natural iron-binding protein with antimicrobial and anti-inflammatory properties. This parameter change allows treatment of AIEC invasion through a different mechanism that avoids the side-effect profile of conventional medications
2Reliability
If lactoferrin is used to prevent AIEC invasion, then AIEC adhesion and internalization are inhibited, but the formulation must ensure adequate release and availability at the site of action
Solution Approach 1:
The formulation is designed to release lactoferrin locally at the site of AIEC invasion in the gastrointestinal tract. The modified release system ensures that lactoferrin becomes available where it is needed most - in contact with AIEC bacteria on the intestinal mucosa - providing localized therapeutic action without requiring complex systemic delivery mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lactoferrin formulation effectively prevents AIEC invasion and reduces inflammation without cytotoxic or bactericidal effects, maintaining remission in patients with Crohn's disease and other IBDs, offering a side-effect-free treatment for chronic inflammatory conditions.
Implementation Method 1
Lactoferrin (Lf), a member of the tranferrin family of iron-binding glycoproteins
Implementation Method 2
Biological properties reported for Lf include antimicrobial activity against a wide range of pathogenic bacteria
Implementation Method 3
a modified release formulation comprising lactoferrin for use in the treatment of inflammatory bowel disease associated with Adherent-invasive Escherichia coli (AIEC) invasion
Data Source
Figure 1~2
Figure 3A~3C
Figure 4A~4B
AI summary
The present invention relates to a substance and an oral formulation for modified release dosage for use in the treatment of inflammatory bowel disease due to Escherichia coli invasion.